A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, latest, Myeloma, NewsJuly 17, 2024
Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, MyelomaApril 18, 2024
European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaMarch 21, 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, latest, MyelomaJuly 9, 2024
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights AL amyloidosis, Conferences, MPE, MyelomaJune 14, 2023
MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapyMyelomaDecember 19, 2023
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, MyelomaApril 23, 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, MyelomaApril 23, 2024
